Exabis Library
Welcome to the e-CCO Library!
P381: An observational study of adverse events of patients with inflammatory bowel disease receiving parenteral iron
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P381: Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P381: Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P381: Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P381: Predictors of vedolizumab response to induction: Real-life experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P381: Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P382 Application of enhanced recovery after surgery in single-port laparoscopic partial small intestine resection in the treatment of Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P382: A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P382: Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P382: Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P382: CRP/albumin ratio: Predictive factor of the response to corticosteroids in acute severe colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P382: High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P382: Novel Image Enhanced Endoscopy (IEE) technologies for surveillance of colonic Inflammatory Bowel Disease: A pilot study evaluating Texture and Colour Enhancement Imaging (TXI) and Linked Colour Imaging (LCI) as compared with chromoendoscopy.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P382: Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P383 The level of intestinal inflammation and fibrosis in resection specimens after preoperative anti-tumour necrosis factor-α treatment in patients with Crohn’s disease: a comparative pilot study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P383: Breast feeding practices differ between mothers with IBD and mothers without IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P383: Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P383: One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P383: Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P383: Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM